Overview

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease

Status:
Completed
Trial end date:
2019-06-08
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety, tolerability, and pharmacokinetics of single, ascending doses of ABBV-951 administered as a subcutaneous bolus infusion followed by a continuous subcutaneous infusion in subjects with Parkinson's disease.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie